GSunan makamashi:Venetoclax (ven ET oh klax)
Sunan Alama: Venclexta, Kunshin Farawa na Venclexta

Ana amfani da Venetoclax don magance cutar sankarar lymphocytic na yau da kullun ko ƙananan cutar sankarar bargo a cikin manya.Ana amfani da Venetoclax shi kaɗai ko a hade tare da wasu magungunan ciwon daji don magance waɗannan yanayi.

Ana amfani da Venetoclax a hade tare da azacitidine, decitabine, ko cytarabine don magance cutar sankarar myeloid mai tsanani.Wannan haɗin don amfani ne ga manya waɗanda shekarunsu suka wuce 75 ko sama da haka, ko waɗanda ba za su iya amfani da daidaitaccen chemotherapy ba saboda wasu yanayin kiwon lafiya.

Ana ba da Venetoclax wani lokaci bayan wasu jiyya sun gaza.

Hakanan za'a iya amfani da Venetoclax don dalilan da ba a lissafa a cikin wannan jagorar magani ba.

Bayani

Venetoclax (ABT-199; GDC-0199) mai ƙarfi ne mai ƙarfi, zaɓi kuma mai hanawa ta baki mai hanawa Bcl-2 tare da Ki na ƙasa da 0.01 nM.Venetoclax yana haifar da autophagy.

A cikin Vitro

Venetoclax (ABT-199) yana kashe ƙwayoyin FL5.12-BCL-2 (EC50 = 4 nM), Venetoclax (ABT-199) yana nuna rashin ƙarfi sosai akan ƙwayoyin FL5.12-BCL-XL (EC50 = 261 nM).ABT-199 yana nuna sauyawa a cikin magungunan Mammalian biyu-hudu, inda ya rushe katangar Bcl-2-batsa (EC50 = 3 nm) amma yana da ƙarancin inganci a kan BCL-XL-BCL-XS (EC50 = 2.2μM) ko MCL-1-NOXA.

Bayan kashi ɗaya na baka na 12.5 MG a kowace kilogiram na nauyin jiki a cikin xenografts da aka samo daga RS4; 11 Kwayoyin (ALL), Venetoclax (ABT-199) yana haifar da haɓakar haɓakar ƙwayar ƙwayar cuta (TGImax) na 47% (P <0.001) da haɓakar ƙwayar cuta jinkirta (TGD) na 26% (P<0.05)[1].

Jiyya na xenograft da aka kafa (samfurin xenograft linzamin kwamfuta na T-ALL cell line LOUCY) ciwace-ciwacen daji tare da Venetoclax (ABT-199) 100 mg / kg na kwanaki 4 yana haifar da raguwa mai yawa na nauyin leukemic.